Post-effective amendment to a registration statement that is not immediately effective upon filing

Net Loss per Share

v3.23.1
Net Loss per Share
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]    
Net Loss per Share

Note 9: Net Loss per Share

The following table provides the computation of basic and diluted net loss per share:

    

Three Months Ended March 31,

    

2023

    

2022

(in thousands, except per share data)

Net loss attributable to Class A common stockholders–basic and diluted

$

(9,199)

$

(10,577)

Weighted average Class A common shares outstanding–basic and diluted

 

41,579

 

41,579

Net loss per share attributable to Class A common stockholders–basic and diluted

$

(0.22)

$

(0.25)

Shares of Class V common stock do not share in the earnings or losses of P3 Health Partners, Inc. and are therefore not participating securities. As such, separate presentation of basic and diluted net income per share for Class V common stock under the two-class method is not required. The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive.

    

Three Months Ended March 31,

    

2023

    

2022

(in thousands)

Stock warrants (1)

 

11,248

 

10,819

Stock options (1)

 

5,487

 

2,134

Shares of Class V common stock (2)

 

201,972

 

202,025

Total

 

218,707

 

214,978

(1) Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share.
(2) Shares of Class V common stock at the end of the period, including shares tied to unvested Common Units, are considered potentially dilutive shares of Class A common stock under the application of the if-converted method.

Note 16: Loss per Share

The following table provides the computation of basic and diluted net loss per share:

Year Ended

December 3, 2021

December 31, 

through December 31,

    

2022

    

2021

Net loss attributable to Class A common stockholders-basic and diluted

$

(270,127)

$

(10,081)

Weighted average Class A common shares outstanding-basic and diluted

41,579

41,579

Loss per share attributable to Class A common stockholders-basic and diluted

$

(6.50)

$

(0.24)

Shares of Class V common stock do not share in the earnings or losses of P3 Health Partners, Inc. and are therefore not participating securities. As such, separate presentation of basic and diluted net income per share for Class V common stock under the two-class method is not required. The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive.

Year Ended

December 3, 2021

December 31, 

through December 31,

    

2022

    

2021

Stock warrants(1)

11,248

10,819

Stock options(1)

3,402

Shares of Class V common stock(2)

201,972

202,025

Total

216,622

212,844

(1) Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share
(2) Shares of Class V common stock at the end of the period, including shares tied to unvested Common Units, are considered potentially dilutive shares of Class A common stock under application of the if-converted method.